




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

A





Figure 6

B


Secondary structure prediction
of therapeutic U1s
with relatively lower efficiency
but little structure distance
from the endogenous U1

RNAfold


human endogenous U1



therapeutic: -9



therapeutic: +4



therapeutic: +5




Figure 6




Figure 7




Figure 8




Figure 8


Stargardt disease condition: mechanism

Figure 9




Figure 10




Figure 11

A




Figure 12

B





Figure 12

A



B




Figure 13